This cohort study compares plasma levels of phosphorylated tau at threonine 217 with established cerebrospinal fluid and positron emission tomography (PET) tau biomarkers in early Alzheimer disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.